Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)

Next Previous
Search
Trial Profile

A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisocabtagene-maraleucel (Primary) ; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Fludarabine; Gemcitabine; Ifosfamide; Melphalan; Rituximab
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TRANSFORM
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 13 Jan 2025 According to a Bristol Myers Squibb media release, company announced Health Canada approval of Breyanzi (lisocabtagene maraleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL). The Health Canada approval is supported by results from the pivotal Phase 3 TRANSFORM trial.
    • 09 Dec 2024 According to a Bristol Myers Squibb media release, data from this study were presented at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
    • 19 Nov 2024 According to a Bristol Myers Squibb media release, results from this trial will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 7 to 10 in San Diego, California.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top